Vycor Medical, Inc. (VYCO) Fair Value 2026

VYCO · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 3 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-10-07, Vycor Medical, Inc. (VYCO) trades at $0.07, versus a $0.06 median fair value across its 3 active models — 15.0% below the current price. QOC: 6.0/10. Value Trap Risk: 26/100 (LOW). 3/13 models active.

Key Facts

Ticker
VYCO
Price
$0.07
Quality Score
6.0/10
Value Trap Risk
26/100
Models Active
3/13
Last Updated
Strength: First Chicago suggests +2.3% upside with 58% confidence
Risk: Majority of models suggest overvaluation

Is Vycor Medical, Inc. (VYCO) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Vycor Medical, Inc. (VYCO) appears overvalued as of : the median of 3 independent fair value estimates is $0.06, 15.0% below the current price of $0.07. Estimates range from $0.04 to $0.07. VYCO scores 6.0/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. VYCO’s -15.0% gap is narrower than that market norm, and the Medical Devices sector median is -41.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Vycor Medical, Inc. Stock in 2026? →

What Fair Value Does Each Model Give VYCO?

3 Intrinsic Value Models vs. Current Price ($0.07)

Core Models (Unlocked)
Model Fair Value Upside
Scenario · High Conviction
 $0.07 +2.3%
Hybrid · Medium Conviction
 $0.04 -41.9%
Relative · Low Conviction
 $0.06 -15.0%

All Models Active

All 3 models are displayed above.

What Is VYCO's Fair Value Range?

Spread across 3 independent models · $0.04 to $0.07

CirclFi's 3 active models place Vycor Medical, Inc. (VYCO) between $0.04 and $0.07 per share, a spread of 52% of the median. The median of that range — $0.06 — is the fair value CirclFi publishes for VYCO, against a current price of $0.07.

Low · Sentiment SOTPHigh · First Chicago
$0.04median $0.06$0.07
Where the range comes from
Most bearish modelSentiment SOTP$0.04
Most bullish modelFirst Chicago$0.07
Model agreement0 bullish · 2 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on VYCO, not a CirclFi price target. How each model works →

What Is Vycor Medical, Inc. (VYCO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Vycor Medical, Inc. at its current price of $0.07. The median intrinsic value is estimated at $0.06 (-15.0% vs price), with 2 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $0.07 (+2.3%), while Sentiment SOTP — the most conservative — estimates $0.04 (-41.9%). This +44.2% gap reflects genuine analytical uncertainty about Vycor Medical, Inc.'s intrinsic worth.

What Do the Models Say About VYCO?

3 of 13 models are currently active for VYCO. Of these, 1 model suggests upside while 2 models suggest overvaluation. Taken together, their median fair value for VYCO is $0.06 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does VYCO Rank in Medical Devices?

Among 161 Medical Devices stocks, VYCO ranks #93 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

As a pharmaceutical industry, Vycor Medical, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating VYCO should weigh these sector-specific dynamics alongside our model-derived fair values.

Is VYCO a Value Trap?

CirclFi's Value Trap algorithm assigns VYCO a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Vycor Medical, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Vycor Medical, Inc.'s fundamental quality profile registers 6.0/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +44.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every VYCO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across VYCO's 3 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Vycor Medical, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

AIDX20/20 Biolabs, Inc.QOC 6.0SSIISS Innovations International, Inc.QOC 6.0RPIDRapid Micro Biosystems, Inc.QOC 6.1BTCYBiotricity, Inc.QOC 6.0NMTCNeuroOne Medical Technologies CorporationQOC 6.1LABStandard BioTools Inc.QOC 5.9ALURAllurion Technologies Inc.QOC 4.8ABTAbbott LaboratoriesQOC 8.8MXCTMaxCyte, Inc.QOC 7.0IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: AIDX · SSII · RPID · BTCY · NMTC · LAB · ALUR · ABT · MXCT · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to VYCO?

7 companies across all industries closest to VYCO’s Quality of Company score of 6.0/10.

IEIvanhoe Electric Inc.QOC 6.0MTEXMannatech, IncorporatedQOC 6.0TISITeam, Inc.QOC 6.0KLNGKoil Energy Solutions, Inc.QOC 6.0ORKTOrangekloud Technology Inc.QOC 6.0TPCSTechPrecision CorporationQOC 6.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: IE · MTEX · TISI · KLNG · ORKT · TPCS · NVDA

Where Does VYCO Sit in CirclFi's Medical Devices Rankings?

VYCO is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Vycor Medical, Inc.’s Valuation?

What is Vycor Medical, Inc.'s intrinsic value in 2026?

CirclFi puts Vycor Medical, Inc. (VYCO)'s intrinsic value at $0.06 — the median of 3 independent model estimates as of 2026-10-07, ranging from $0.04 to $0.07. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is VYCO overvalued or undervalued right now?

At $0.07, 1 of 3 active models suggest VYCO may be undervalued, while 2 indicate potential overvaluation. The median of all 3 fair value estimates is $0.06, 15.0% below the current price of $0.07 — a consensus view that VYCO is overvalued. The assessment depends on which methodology best fits Vycor Medical, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.0 mean for VYCO?

Vycor Medical, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on VYCO?

CirclFi analyzes VYCO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on VYCO?

Of the 3 models currently active on VYCO, First Chicago is the most bullish at $0.07 per share, and Sentiment SOTP is the most bearish at $0.04. CirclFi's published fair value for VYCO is the median of that range, $0.06, not either extreme. The gap between the two ends equals 52% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is VYCO a value trap in 2026?

Vycor Medical, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Vycor Medical, Inc. (VYCO) has a median fair value of $0.06 — 15.0% below the current price of $0.07 — as of 2026-10-07.” Source: circlfi.com/stock/VYCO/ · Methodology
Primary sources for this VYCO valuation
  • Financial statements: Vycor Medical, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001424768) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for VYCO as of ; valuations recomputed .